FX.co ★ Moleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AML

Moleculin Biotech, Inc. announced on Monday, positive preliminary results from the MB-106 Phase 1B/2 study of Annamycin combined with Cytarabine for treating patients with Acute Myeloid Leukemia (AML). This combination of Annamycin and Cytarabine, also referred to as AnnAraC, produced a complete response composite (CRc) rate of 60% amongst patients undergoing 2nd line treatment for AML. Moleculin's Chairman and CEO, Walter Klemp, expressed that the 60% CRc rate as a 2nd line therapy and with half of those being full CRs, shows the potential of AnnAraC to offer a viable alternative treatment for 2nd line patients, irrespective of their prior treatments or mutations.